Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Shielding against radiation will not only help people survive nuclear fallout but also improve health outcomes for cancer ...

Hundreds of people with aggressive blood cancer will be offered a groundbreaking one-off personalised therapy that ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand with ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...